皓元醫藥(688131.SH):蘇信基金減持65.87萬股公司股份
格隆匯5月20日丨皓元醫藥(688131.SH)公佈,公司於2025年5月20日收到蘇民投君信(上海)產業升級與科技創新股權投資合夥企業(有限合夥)(以下簡稱“蘇信基金”)出具的《關於減持股份權益變動觸及1%的告知函》,2025年4月1日至2025年5月20日期間,蘇信基金通過集中競價的方式減持公司股份658,742股,所持有公司股份數量由13,238,158股減少至12,579,416股,佔公司當前總股本的比例由6.28%減少至5.96%,觸及1%的整數倍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.